Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 11: Drug-induced colitis is most frequently associated with which of the following medications?

A. Neomycin
B. Vancomycin
C. Clindamycin (Correct Answer)
D. Chloramphenicol

Explanation: **Explanation:** The correct answer is **Clindamycin**. **1. Why Clindamycin is correct:** Clindamycin is the antibiotic most classically associated with **Pseudomembranous Colitis (PMC)**. The underlying mechanism involves the suppression of normal protective gut flora, which allows for the overgrowth of the toxin-producing bacterium ***Clostridioides difficile*** (formerly *Clostridium difficile*). These toxins (Toxin A and B) cause mucosal inflammation and the formation of characteristic "pseudomembranes" on the colonic wall. While almost any antibiotic can cause PMC, clindamycin carries the highest relative risk. **2. Why the other options are incorrect:** * **Neomycin:** This is an aminoglycoside primarily used for bowel preparation or hepatic encephalopathy. It is poorly absorbed and more commonly associated with malabsorption syndromes rather than colitis. * **Vancomycin:** Oral vancomycin is actually a **treatment** of choice for *C. difficile* colitis. It is not a common cause of the condition because it is highly effective against the causative organism. * **Chloramphenicol:** While it has significant side effects like bone marrow suppression (Aplastic anemia) and Gray Baby Syndrome, it is not a frequent cause of drug-induced colitis. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** For the first episode of *C. difficile* colitis, the current guidelines recommend **Fidaxomicin** or **Oral Vancomycin**. (Metronidazole is now reserved for mild cases or where others are unavailable). * **Diagnosis:** The gold standard for diagnosis is the detection of *C. difficile* toxins in the stool via PCR or Enzyme Immunoassay (EIA). * **Common Culprits:** Besides Clindamycin, other high-risk groups include Fluoroquinolones, Cephalosporins (2nd/3rd gen), and broad-spectrum Penicillins.

Question 12: What is the most specific antiemetic for chemotherapy-induced vomiting?

A. Granisetron (Correct Answer)
B. Tegaserod
C. Domperidone
D. Doxylamine

Explanation: **Explanation:** **1. Why Granisetron is the correct answer:** Chemotherapy-induced nausea and vomiting (CINV) are primarily mediated by the release of serotonin (5-HT) from enterochromaffin cells in the GI tract, which stimulates **5-HT₃ receptors** on vagal afferents and the Chemoreceptor Trigger Zone (CTZ). **Granisetron** is a potent, highly selective 5-HT₃ receptor antagonist. It is considered the "gold standard" or most specific class for acute CINV because it blocks the primary pathway triggered by emetogenic drugs like Cisplatin. **2. Why the other options are incorrect:** * **Tegaserod:** This is a **5-HT₄ partial agonist** used for Irritable Bowel Syndrome with constipation (IBS-C). It stimulates GI motility rather than inhibiting the vomiting reflex. * **Domperidone:** This is a **D₂ receptor antagonist**. While it has prokinetic and antiemetic properties, it is significantly less effective than 5-HT₃ antagonists for the intense stimulus of chemotherapy. * **Doxylamine:** This is an **H₁ antihistamine** with anticholinergic properties. It is primarily used for morning sickness (vomiting in pregnancy), often in combination with Pyridoxine (Vitamin B6), but is ineffective for CINV. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** 5-HT₃ antagonists (Ondansetron, Granisetron, Palonosetron) are the DOC for **acute** CINV. * **Palonosetron:** Has the longest half-life in its class and is effective for both acute and delayed CINV. * **Aprepitant:** A Neurokinin-1 (NK₁) receptor antagonist, often added to 5-HT₃ antagonists and dexamethasone for highly emetogenic regimens to prevent **delayed** vomiting. * **Side Effects:** The most common side effects of 5-HT₃ antagonists are **headache**, constipation, and **QT interval prolongation** (except Palonosetron).

Question 13: Terlipressin is preferred over vasopressin for esophageal varices because of which of the following reasons?

A. Faster onset of action
B. Not metabolized
C. Fewer side effects (Correct Answer)
D. More potent

Explanation: **Explanation:** **Terlipressin** is a synthetic analogue of vasopressin (antidiuretic hormone) and is considered the drug of choice for the management of acute variceal bleeding. **Why "Fewer side effects" is correct:** The primary reason Terlipressin is preferred over Vasopressin is its **superior safety profile**. Vasopressin is a non-selective vasoconstrictor that acts on both $V_1$ and $V_2$ receptors, leading to significant systemic side effects, most notably **coronary and mesenteric ischemia**. Terlipressin, however, acts as a "prodrug" that is slowly converted to lysine-vasopressin in the body. This provides a sustained, low-dose release, resulting in more selective splanchnic vasoconstriction with significantly lower risks of cardiac and systemic complications. **Analysis of Incorrect Options:** * **A. Faster onset of action:** Incorrect. Because Terlipressin is a prodrug that requires enzymatic cleavage to become active, its onset is actually slower than the immediate action of intravenous Vasopressin. * **B. Not metabolized:** Incorrect. Terlipressin is actively metabolized (cleaved by endopeptidases) to its active form, lysine-vasopressin. * **C. More potent:** Incorrect. While Terlipressin is effective, the clinical preference is based on its **duration of action** (longer half-life allowing bolus doses) and **safety**, rather than absolute potency. **NEET-PG High-Yield Pearls:** * **Mechanism:** Terlipressin causes splanchnic vasoconstriction, reducing portal venous pressure and blood flow to the varices. * **Administration:** Unlike Vasopressin (which requires continuous IV infusion), Terlipressin can be given as **intermittent IV bolus** injections every 4–6 hours. * **Other Uses:** It is also the drug of choice for **Hepatorenal Syndrome (HRS)**. * **Key Side Effect:** Watch for hyponatremia (due to $V_2$ receptor activity).

Question 14: Which of the following is NOT a side effect of long-term use of proton pump inhibitors?

A. Hypothyroidism (Correct Answer)
B. Osteoporosis leading to hip fracture
C. Community-acquired pneumonia
D. Clostridium difficile infection

Explanation: **Explanation:** Proton Pump Inhibitors (PPIs) like omeprazole and pantoprazole are generally safe but are associated with specific adverse effects when used long-term due to the chronic suppression of gastric acid. **Why Hypothyroidism is the correct answer:** PPIs do **not** cause hypothyroidism. In fact, the relationship is the opposite: because PPIs increase gastric pH, they can **decrease the absorption of oral Levothyroxine** (which requires an acidic environment for optimal dissolution). Therefore, patients with existing hypothyroidism may require higher doses of thyroid replacement therapy if they start a PPI, but the drug itself does not induce thyroid dysfunction. **Analysis of incorrect options (Known side effects of PPIs):** * **Osteoporosis (Option B):** Chronic acid suppression reduces the ionization and absorption of calcium (especially calcium carbonate). Long-term use is linked to decreased bone mineral density and an increased risk of hip and wrist fractures. * **Community-acquired pneumonia (Option C):** Increased gastric pH allows for bacterial overgrowth in the stomach. These bacteria can be micro-aspirated into the respiratory tract, increasing the risk of pneumonia. * **Clostridium difficile infection (Option D):** Gastric acid is a primary defense against ingested pathogens. Its absence alters the gut microbiome, significantly increasing the risk of *C. difficile* associated diarrhea and other enteric infections like *Salmonella*. **NEET-PG High-Yield Pearls:** * **Hypomagnesemia:** Long-term PPI use can lead to severe magnesium deficiency (due to impaired intestinal absorption). * **Vitamin B12 Deficiency:** Acid is required to release B12 from dietary protein; chronic PPI use can lead to megaloblastic anemia. * **Hypergastrinemia:** Chronic inhibition of the proton pump leads to a compensatory increase in gastrin, which may cause hyperplasia of ECL cells.

Question 15: Teduglutide is a recently introduced drug for short bowel syndrome. What is it?

A. GLP antagonist
B. Somatostatin analogue
C. H1 blocker
D. GLP-2 analogue (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. GLP-2 analogue** **Teduglutide** is a recombinant human **Glucagon-Like Peptide-2 (GLP-2) analogue**. In patients with Short Bowel Syndrome (SBS), the primary clinical challenge is malabsorption due to reduced mucosal surface area. * **Mechanism of Action:** Teduglutide binds to GLP-2 receptors located in the intestinal subepithelial myofibroblasts. This triggers the release of various growth factors (like IGF-1), which promotes **mucosal hypertrophy** and increases villus height and crypt depth. * **Clinical Effect:** It enhances intestinal absorptive capacity, thereby reducing the dependency on parenteral nutrition (PN) in patients with SBS. **Why other options are incorrect:** * **A. GLP antagonist:** There is no clinical role for GLP-2 antagonists in SBS; we aim to *stimulate* growth, not inhibit it. * **B. Somatostatin analogue:** Drugs like **Octreotide** are used in SBS to reduce secretory diarrhea and stoma output, but they do not promote intestinal adaptation or mucosal growth. * **C. H1 blocker:** These are antihistamines used for allergic conditions or motion sickness (e.g., Promethazine) and have no role in intestinal mucosal regeneration. **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Administered via subcutaneous injection. * **Major Side Effect:** Because it promotes cell growth, there is a theoretical risk of **neoplasia** (polyps). Colonoscopy is mandatory before starting therapy and during follow-up. * **Other Drugs for SBS:** * **Somatropin:** A recombinant Growth Hormone (GH) also used to increase protein synthesis and mucosal transport. * **Glutamine:** Often used as an adjuvant to provide fuel for enterocytes.

Question 16: Activation of which type of receptors present on myenteric neurons by metoclopramide is primarily responsible for the enhanced acetylcholine release and improving gastric motility?

A. Muscarinic M1
B. Serotonergic 5-HT3
C. Serotonergic 5-HT4 (Correct Answer)
D. Dopaminergic D2

Explanation: ### Explanation **Correct Option: C. Serotonergic 5-HT4** Metoclopramide is a substituted benzamide that acts as a **prokinetic agent**. Its primary mechanism for enhancing gastrointestinal motility is the **agonism of 5-HT4 receptors** located on the presynaptic terminals of excitatory myenteric neurons. Activation of these receptors triggers the release of **Acetylcholine (ACh)** at the neuromuscular junction, which stimulates the smooth muscle of the stomach and upper intestine, leading to increased gastric emptying and intestinal transit [1]. **Analysis of Incorrect Options:** * **A. Muscarinic M1:** While ACh eventually acts on M3 receptors on smooth muscles to cause contraction, metoclopramide does not directly activate M1 receptors to enhance motility. * **B. Serotonergic 5-HT3:** Metoclopramide is a 5-HT3 **antagonist**. This action occurs primarily in the Chemoreceptor Trigger Zone (CTZ) and contributes to its **antiemetic** properties, not its prokinetic effect. * **D. Dopaminergic D2:** Metoclopramide is a D2 receptor antagonist. While D2 blockade in the GI tract contributes slightly to the prokinetic effect (as dopamine inhibits ACh release), the **primary** and more potent driver of gastric motility is 5-HT4 agonism. D2 blockade in the CTZ is also responsible for its antiemetic effect. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Metoclopramide is both a prokinetic (via 5-HT4 agonism) and an antiemetic (via D2 and 5-HT3 antagonism). * **Side Effects:** Due to central D2 blockade, it can cause **extrapyramidal symptoms** (dystonias, Parkinsonism) and **hyperprolactinemia** (galactorrhea, gynecomastia). * **Drug of Choice:** It is frequently used in diabetic gastroparesis and as an antiemetic in postoperative nausea. * **Contraindication:** Never use in cases of mechanical GI obstruction or pheochromocytoma (may cause hypertensive crisis).

Question 17: What is the primary use of Calcium Carbonate?

A. Antacid (Correct Answer)
B. Renal stone
C. Metabolic alkalosis
D. Renal failure

Explanation: **Explanation:** **Calcium Carbonate** is a potent, non-systemic antacid. Its primary mechanism involves the direct neutralization of gastric hydrochloric acid (HCl), forming calcium chloride, water, and carbon dioxide ($CO_2$). This rapid neutralization increases the gastric pH, providing immediate relief from symptoms of dyspepsia and GERD. **Analysis of Options:** * **A. Antacid (Correct):** It is the most common clinical use. It has a high neutralizing capacity; however, it can cause "acid rebound" due to the release of gastrin and may lead to constipation. * **B. Renal Stone (Incorrect):** Calcium carbonate is generally contraindicated or used with extreme caution in patients with a history of calcium oxalate stones, as it can increase urinary calcium levels (hypercalciuria), potentially worsening the condition. * **C. Metabolic Alkalosis (Incorrect):** Excessive intake of calcium carbonate, especially with milk, can *cause* Milk-Alkali Syndrome, which is characterized by hypercalcemia and metabolic alkalosis. It is not a treatment for it. * **D. Renal Failure (Incorrect):** While calcium carbonate is used as a **phosphate binder** in chronic kidney disease (CKD) to manage hyperphosphatemia, it is not a treatment for renal failure itself. Furthermore, in advanced renal failure, there is a risk of hypercalcemia and metastatic calcification. **High-Yield Clinical Pearls for NEET-PG:** * **Milk-Alkali Syndrome:** A classic triad of hypercalcemia, metabolic alkalosis, and renal insufficiency associated with high calcium carbonate intake. * **Acid Rebound:** Calcium ions directly stimulate gastrin receptors on parietal cells, leading to secondary acid secretion once the antacid effect wears off. * **Drug Interactions:** Like other antacids, it can decrease the absorption of drugs like Tetracyclines, Iron, and Fluoroquinolones due to chelation.

Question 18: Which anticholinergic drug has a comparatively specific action on gastric secretion and is useful in peptic ulcer?

A. Atropine
B. Pirenzepine (Correct Answer)
C. Oxyphenonium bromide
D. Dicyclomine

Explanation: **Explanation:** The correct answer is **Pirenzepine**. **1. Why Pirenzepine is correct:** Pirenzepine is a selective **M1-receptor antagonist** [1]. In the stomach, M1 receptors are located on the intramural ganglia of the vagus nerve. By blocking these receptors, pirenzepine inhibits the release of acetylcholine, which in turn reduces gastric acid secretion from parietal cells [1]. Unlike non-selective anticholinergics, it has a higher affinity for gastric M1 receptors than for M2 (heart) or M3 (smooth muscle/glands) receptors, allowing it to reduce acid secretion at doses that do not significantly cause typical anticholinergic side effects like tachycardia or dry mouth [1]. **2. Why the other options are incorrect:** * **Atropine:** A prototype non-selective muscarinic antagonist [1]. It blocks M1, M2, and M3 receptors equally [3]. To inhibit gastric acid, it requires high doses that cause intolerable side effects (blurred vision, urinary retention, tachycardia) [1], [2]. * **Oxyphenonium bromide:** A potent non-selective synthetic anticholinergic. While used as an antispasmodic and adjunct in peptic ulcers, it lacks the M1-selectivity of pirenzepine. * **Dicyclomine:** Primarily acts as a direct smooth muscle relaxant and M3 antagonist [4]. It is used as an **antispasmodic** for Irritable Bowel Syndrome (IBS) and abdominal colic, rather than for suppressing gastric acid [4]. **NEET-PG High-Yield Pearls:** * **Telenzepine** is another M1-selective antagonist, even more potent than pirenzepine [1]. * While pirenzepine is pharmacologically significant, it is rarely used clinically today due to the superior efficacy of **Proton Pump Inhibitors (PPIs)** and H2 blockers. * **M1 Receptors:** Located in Autonomic ganglia and CNS [3]. * **M2 Receptors:** Located in the Heart (SA/AV node). * **M3 Receptors:** Located in Smooth muscles, Exocrine glands, and Vascular endothelium.

Question 19: Which antiulcer agent detaches from and kills H. Pylori, thereby preventing relapses?

A. Colloidal Bismuth (Correct Answer)
B. Pirenzipine
C. Misoprostol
D. Sucralfate

Explanation: **Explanation:** The correct answer is **Colloidal Bismuth Subcitrate (CBS)**. **Why Colloidal Bismuth is correct:** Colloidal Bismuth acts via multiple mechanisms to treat peptic ulcers. Unlike most antiulcer drugs that merely reduce acid or provide a physical barrier, Bismuth compounds possess direct **antimicrobial activity** against *H. pylori*. 1. **Detachment:** It prevents the adhesion of *H. pylori* to the gastric epithelium. 2. **Bactericidal Action:** It causes lysis of the bacterial wall and inhibits its enzymes (like urease and phospholipase). By eradicating the bacteria, it significantly reduces the rate of ulcer relapse compared to drugs that only suppress acid. **Why other options are incorrect:** * **Pirenzepine:** An M1-selective anticholinergic that reduces gastric acid secretion. It has no effect on *H. pylori* and is rarely used due to the superiority of PPIs. * **Misoprostol:** A PGE1 analogue that increases mucosal bicarbonate/mucus and decreases acid. It is primarily used for preventing NSAID-induced ulcers but lacks antimicrobial properties. * **Sucralfate:** A physical mucosal protectant that polymerizes at pH < 4 to form a "sticky paste" over the ulcer base. While it provides a barrier, it does not kill *H. pylori*. **High-Yield NEET-PG Pearls:** * **Bismuth Quadruple Therapy:** Consists of a PPI + Bismuth + Metronidazole + Tetracycline (used as first-line or for resistant *H. pylori*). * **Side Effects:** Bismuth can cause **black discoloration of stools and tongue** (may be confused with melena) and, rarely, encephalopathy with long-term use. * **Sucralfate Requirement:** It requires an acidic medium for activation; therefore, it should **not** be given simultaneously with antacids or PPIs.

Question 20: All are included in triple therapy for peptic ulcer EXCEPT:

A. Clarithromycin
B. Amoxicillin
C. Ciprofloxacin (Correct Answer)
D. Proton pump inhibitor

Explanation: The standard treatment for *Helicobacter pylori* associated peptic ulcer disease is **Triple Therapy**, typically administered for 10–14 days. ### **Explanation of the Correct Answer** **C. Ciprofloxacin** is the correct answer because it is **not** a component of the standard first-line triple therapy. While fluoroquinolones like Levofloxacin are sometimes used in "Levofloxacin-based triple therapy" as a second-line or rescue treatment for resistant cases, Ciprofloxacin specifically is not part of the established protocols for *H. pylori* eradication. ### **Analysis of Incorrect Options** * **A. Clarithromycin:** A macrolide antibiotic that inhibits bacterial protein synthesis. It is a cornerstone of triple therapy due to its high efficacy against *H. pylori*. * **B. Amoxicillin:** A penicillin derivative that inhibits cell wall synthesis. It is preferred because resistance to amoxicillin is rare. In patients allergic to penicillin, **Metronidazole** is used as a substitute. * **D. Proton Pump Inhibitor (PPI):** Drugs like Omeprazole or Lansoprazole are essential. They increase gastric pH, which not only promotes ulcer healing but also enhances the stability and antimicrobial activity of the antibiotics. ### **High-Yield Clinical Pearls for NEET-PG** * **Standard Triple Therapy Regimen (CAP):** **C**larithromycin (500mg BD) + **A**moxicillin (1g BD) + **P**PI (Standard dose BD). * **Sequential Therapy:** Involves a PPI + Amoxicillin for 5 days, followed by a PPI + Clarithromycin + Tinidazole for the next 5 days. * **Pylera (Quadruple Therapy):** Used in areas of high clarithromycin resistance. It includes a **PPI + Bismuth subsalicylate + Metronidazole + Tetracycline**. * **Drug of Choice:** PPIs are the most effective drugs for inhibiting gastric acid secretion and are the DOC for NSAID-induced ulcers and Zollinger-Ellison Syndrome.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free